Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Edwin DeJesus, MD, FACP,
Orlando Immunology Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cd02 Investigational Site
Ponce, PR, Puerto Rico
- Cd02 Investigational Site
San Juan, Puerto Rico
- Cd02 Investigational Site
Fountain Valley, California, United States
- Cd02 Investigational Site
Long Beach, California, United States
- Cd02 Investigational Site
Los Angeles, California, United States
- Cd02 Investigational Site
Los Angeles, California, United States
- Cd02 Investigational Site
Palm Springs, California, United States
- Cd02 Investigational Site
San Francisco, California, United States
- Cd02 Investigational Site
San Francisco, California, United States
- Cd02 Investigational Site
New Haven, Connecticut, United States
- Cd02 Investigational Site
Norwalk, Connecticut, United States
- Cd02 Investigational Site
Washington D.C., District of Columbia, United States
- Cd02 Investigational Site
Washington D.C., District of Columbia, United States
- Cd02 Investigational Site
Clearwater, Florida, United States
- Cd02 Investigational Site
Ft. Pierce, Florida, United States
- Cd02 Investigational Site
Miami, Florida, United States
- Cd02 Investigational Site
Miami, Florida, United States
- Cd02 Investigational Site
Miami, Florida, United States
- Cd02 Investigational Site
Miami Beach, Florida, United States
- Cd02 Investigational Site
Orlando, Florida, United States
- Cd02 Investigational Site
West Palm Beach, Florida, United States
- Cd02 Investigational Site
Chicago, Illinois, United States
- Cd02 Investigational Site
Wichita, Kansas, United States
- E Study Site
Las Vegas, Nevada, United States
- Cd02 Investigational Site
New York, New York, United States
- Cd02 Investigational Site
New York, New York, United States
- Cd02 Investigational Site
Syracuse, New York, United States
- Cd02 Investigational Site
Charlotte, North Carolina, United States
- Cd02 Investigational Site
Cincinnati, Ohio, United States
- Cd02 Investigational Site
Austin, Texas, United States
- Cd02 Investigational Site
Bellaire, Texas, United States
- Cd02 Investigational Site
Dallas, Texas, United States
- Cd02 Investigational Site
Houston, Texas, United States
- Cd02 Investigational Site
Houston, Texas, United States
- Cd02 Investigational Site
Annandale, Virginia, United States
- Cd02 Investigational Site
Spokane, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2015
- Primary completion
- 28 Feb 2018
- Completion
- 31 Jul 2018
- Last update posted
- 3 Nov 2022
- Registered enrollment
- 52
- Registry id
- NCT02483078
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.